Header Logo

Connection

Christopher Goetz to Movement Disorders

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Movement Disorders.
Christopher Goetz
Connection Strength
9.553
Movement Disorders
  1. Reply to: "The Framework for Diagnostic Criteria in Movement Disorders: The Value of Methodological Tools and Combined Criteria". Mov Disord. 2023 09; 38(9):1763-1764.
    View in: PubMed
    Score: 0.805
  2. Implementation and Outcomes of a Movement Disorder Society-Sponsored Peer Reviewing Education and Mentoring Program. Mov Disord. 2022 05; 37(5):1093-1097.
    View in: PubMed
    Score: 0.727
  3. Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice? Mov Disord. 2021 07; 36(7):1481-1482.
    View in: PubMed
    Score: 0.694
  4. Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era. Mov Disord. 2020 06; 35(6):911.
    View in: PubMed
    Score: 0.640
  5. Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2018 07; 33(7):1189-1190.
    View in: PubMed
    Score: 0.563
  6. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.462
  7. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.374
  8. Dopamine dysregulation syndrome item from the MDS-UPDRS. Mov Disord. 2012 Jan; 27(1):166.
    View in: PubMed
    Score: 0.354
  9. The movement disorder society and movement disorders: a modern history. Mov Disord. 2011 May; 26(6):939-46.
    View in: PubMed
    Score: 0.342
  10. [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. Rev Neurol (Paris). 2010 Jan; 166(1):1-4.
    View in: PubMed
    Score: 0.309
  11. Movement disorders caused by medical disease. Semin Neurol. 2009 Apr; 29(2):97-110.
    View in: PubMed
    Score: 0.297
  12. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
    View in: PubMed
    Score: 0.236
  13. A Unified Framework for Evidence-Based Diagnostic Criteria Programs in Movement Disorders. Mov Disord. 2023 07; 38(7):1156-1162.
    View in: PubMed
    Score: 0.197
  14. Therapies for movement disorders. Arch Neurol. 2002 May; 59(5):699-702.
    View in: PubMed
    Score: 0.183
  15. Seminal figures in the history of movement disorders: Gilles de la Tourette, Oppenheim, the Vogts, von Economo, Wilson, and Marsden. Part 12 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Sep; 16(5):940-6.
    View in: PubMed
    Score: 0.175
  16. Medical art and photography in the history of movement disorders: Part 13 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Sep; 16(5):947-53.
    View in: PubMed
    Score: 0.175
  17. History of movement disorders as a neurological specialty: Part 14 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Sep; 16(5):954-9.
    View in: PubMed
    Score: 0.175
  18. Seminal figures in the history of movement disorders: Sydenham, Parkinson, and Charcot: Part 6 of the MDS-sponsored history of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 May; 16(3):537-40.
    View in: PubMed
    Score: 0.171
  19. Parkinsonism-plus syndromes: Part 7 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 May; 16(3):541.
    View in: PubMed
    Score: 0.171
  20. History of Myoclonus: Part 8 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 May; 16(3):545-7.
    View in: PubMed
    Score: 0.171
  21. History of chorea: part 3 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Mar; 16(2):331-8.
    View in: PubMed
    Score: 0.169
  22. History of dystonia: part 4 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June, 2000. Mov Disord. 2001 Mar; 16(2):339-45.
    View in: PubMed
    Score: 0.169
  23. History of tic disorders and Gilles de la Tourette syndrome: part 5 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001 Mar; 16(2):346-9.
    View in: PubMed
    Score: 0.169
  24. The basal ganglia: part 1 of the MDS-sponsored History of Movement Disorders Exhibit, Barcelona, June 2000. Mov Disord. 2001 Jan; 16(1):152-5.
    View in: PubMed
    Score: 0.167
  25. Telemedicine Use for Movement Disorders: A Global Survey. Telemed J E Health. 2018 12; 24(12):979-992.
    View in: PubMed
    Score: 0.138
  26. Drug-induced movement disorders. Neurol Clin. 1998 Feb; 16(1):125-39.
    View in: PubMed
    Score: 0.137
  27. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018 04; 33(4):651-652.
    View in: PubMed
    Score: 0.136
  28. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord. 1994 Jul; 9(4):390-4.
    View in: PubMed
    Score: 0.107
  29. Trauma and movement disorders. Neurol Clin. 1992 Nov; 10(4):907-19.
    View in: PubMed
    Score: 0.095
  30. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.092
  31. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.080
  32. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50.
    View in: PubMed
    Score: 0.072
  33. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.072
  34. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology. 2008 Apr 15; 70(16 Pt 2):1397-402.
    View in: PubMed
    Score: 0.068
  35. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.063
  36. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.059
  37. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.058
  38. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.055
  39. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004 Sep; 19(9):1020-8.
    View in: PubMed
    Score: 0.054
  40. Development of instruments for abnormal movements: dynamometers, the dynamograph, and tremor recorders. Part 9 of the MDS-Sponsored History of Movement Disorders Exhibit, Barcelona, June 2000. Mov Disord. 2001 Jul; 16(4):736-41.
    View in: PubMed
    Score: 0.043
  41. Development of instruments for abnormal movements: postural sway and gait analyses. Part 10 of the MDS-Sponsored History of Movement Disorders Exhibit, Barcelona, June 2000. Mov Disord. 2001 Jul; 16(4):742-8.
    View in: PubMed
    Score: 0.043
  42. Seminal figures in the History of Movement Disorders: Hammond, Osler, and Huntington. Part 11 of the MDS-Sponsored History of Movement Disorders Exhibit, Barcelona, June 2000. Mov Disord. 2001 Jul; 16(4):749-53.
    View in: PubMed
    Score: 0.043
  43. Movement disorders in Kuru. Mov Disord. 1999 Sep; 14(5):800-4.
    View in: PubMed
    Score: 0.038
  44. Progressive cognitive decline with truncal/limb ataxia and ballistic movements. Mov Disord. 1997 Nov; 12(6):1075-84.
    View in: PubMed
    Score: 0.034
  45. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology. 1996 Dec; 47(6):1493-5.
    View in: PubMed
    Score: 0.032
  46. Neurologic health outcomes and Agent Orange: Institute of Medicine report. Neurology. 1994 May; 44(5):801-9.
    View in: PubMed
    Score: 0.026
  47. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov; 43(11):2227-9.
    View in: PubMed
    Score: 0.025
  48. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord. 1990; 5(3):243-7.
    View in: PubMed
    Score: 0.020
  49. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology. 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3.
    View in: PubMed
    Score: 0.019
  50. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987 Dec; 10(6):522-6.
    View in: PubMed
    Score: 0.017
  51. Gilles de la Tourette on Tourette syndrome. Adv Neurol. 1982; 35:1-16.
    View in: PubMed
    Score: 0.011
  52. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med. 1978 Mar; 88(3):327-31.
    View in: PubMed
    Score: 0.009
  53. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology. 1992 Jul; 42(7):1311-4.
    View in: PubMed
    Score: 0.006
  54. Levodopa-induced myoclonus. Arch Neurol. 1975 May; 32(5):330-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.